
Paolo G Artini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5824212/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Carnitines as Mitochondrial Modulators of Oocyte and Embryo Bioenergetics. Antioxidants, 2022, 11, 745.	2.2	9
2	Oxidative Stress Measurement in Frozen/Thawed Human Sperm: The Protective Role of an In Vitro Treatment with Myo-Inositol. Antioxidants, 2022, 11, 10.	2.2	21
3	Endometrial Dysbiosis Is Related to Inflammatory Factors in Women with Repeated Implantation Failure: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 2481.	1.0	12
4	Metabolic and Molecular Mechanisms of Diet and Physical Exercise in the Management of Polycystic Ovarian Syndrome. Biomedicines, 2022, 10, 1305.	1.4	14
5	Mitochondrial Sirtuins in Reproduction. Antioxidants, 2021, 10, 1047.	2.2	32
6	Exploring Epithelial–Mesenchymal Transition Signals in Endometriosis Diagnosis and In Vitro Fertilization Outcomes. Biomedicines, 2021, 9, 1681.	1.4	11
7	Regulatory Functions of L-Carnitine, Acetyl, and Propionyl L-Carnitine in a PCOS Mouse Model: Focus on Antioxidant/Antiglycative Molecular Pathways in the Ovarian Microenvironment. Antioxidants, 2020, 9, 867.	2.2	26
8	Respiratory Mitochondrial Efficiency and DNA Oxidation in Human Sperm after In Vitro Myo-Inositol Treatment. Journal of Clinical Medicine, 2020, 9, 1638.	1.0	20
9	Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study. Gynecological Endocrinology, 2020, 36, 1062-1069.	0.7	1
10	Effect of <scp>d</scp> -chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women. Gynecological Endocrinology, 2020, 36, 755-759.	0.7	13
11	Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study. Gynecological Endocrinology, 2019, 35, 854-861.	0.7	1
12	â€~Primary gingival and later primary vulval carcinomas arising in lichen planus: report of a case and clinical suggestions for diagnosis of a neglected disease'. Gynecological Endocrinology, 2019, 35, 938-940.	0.7	0
13	Pre-conceptional maternal exposure to cyclophosphamide results in modifications of DNA methylation in F1 and F2 mouse oocytes: evidence for transgenerational effects. Epigenetics, 2019, 14, 1057-1064.	1.3	22
14	SIRT1 participates in the response to methylglyoxal-dependent glycative stress in mouse oocytes and ovary. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1389-1401.	1.8	39
15	Female Infertility and Autoimmunity. ISGE Series, 2018, , 85-92.	0.2	0
16	PCOS and pregnancy: a review of available therapies to improve the outcome of pregnancy in women with polycystic ovary syndrome. Expert Review of Endocrinology and Metabolism, 2018, 13, 87-98.	1.2	16
17	Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecological Endocrinology, 2018, 34, 518-523.	0.7	28
18	Human Breast Milk: Exploring the Linking Ring Among Emerging Components. Frontiers in Pediatrics, 2018, 6, 215.	0.9	31

PAOLO G ARTINI

#	Article	IF	CITATIONS
19	Estrogen treatment in infertile women with premature ovarian insufficiency in transitional phase: a retrospective analysis. Journal of Assisted Reproduction and Genetics, 2018, 35, 475-482.	1.2	11
20	Assisted reproductive technique in women of advanced fertility age. Minerva Ginecologica, 2018, 70, 738-749.	0.8	8
21	Thyroid peroxidase identified in human granulosa cells: another piece to the thyroid-ovary puzzle?. Gynecological Endocrinology, 2017, 33, 574-576.	0.7	28
22	The Natural Carotenoid Crocetin and the Synthetic Tellurium Compound AS101 Protect the Ovary against Cyclophosphamide by Modulating SIRT1 and Mitochondrial Markers. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	1.9	35
23	Inositol and In Vitro Fertilization with Embryo Transfer. International Journal of Endocrinology, 2017, 2017, 1-5.	0.6	20
24	Peroxisome Proliferator-Activated Receptors in Female Reproduction and Fertility. PPAR Research, 2016, 2016, 1-12.	1.1	46
25	Modulating Intrafollicular Hormonal Milieu in Controlled Ovarian Stimulation: Insights From PPAR Expression in Human Granulosa Cells. Journal of Cellular Physiology, 2016, 231, 908-914.	2.0	13
26	MicroRNAs Are Stored in Human MII Oocyte and Their Expression Profile Changes in Reproductive Aging. Biology of Reproduction, 2016, 95, 131-131.	1.2	44
27	Inside the granulosa transcriptome. Gynecological Endocrinology, 2016, 32, 951-956.	0.7	12
28	Biomarkers of Ovarian Ageing. ISGE Series, 2016, , 47-51.	0.2	0
29	Gene Expression in Cumulus Cells and Oocyte Quality. ISGE Series, 2016, , 39-44.	0.2	0
30	Different stimulation protocols for oocyte cryropreservation in oncological patients: a retrospective analysis of single university centre. Gynecological Endocrinology, 2015, 31, 966-970.	0.7	10
31	In Patients with Only One or Two Oocytes, Is IVF-ET or ICSI Better?. ISGE Series, 2015, , 111-117.	0.2	Ο
32	Supplementation with DHEA in Poor Responder Patients. ISGE Series, 2015, , 119-127.	0.2	0
33	Over Hypothyroidism in a Woman Undergoing Controlled Ovarian Hyperstimulation. Endocrine Practice, 2014, 20, e11-e13.	1.1	3
34	Increased levels of oxidative and carbonyl stress markers in normal ovarian cortex surrounding endometriotic cysts. Gynecological Endocrinology, 2014, 30, 808-812.	0.7	18
35	Gene expression profiles of cumulus cells obtained from women treated with recombinant human luteinizing hormone + recombinant human follicle-stimulating hormone or highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone alone. Fertility and Sterility. 2013. 99. 2000-2008.e1.	0.5	28
36	Fertility and endocrine outcome after robot-assisted laparoscopic myomectomy (RALM). Gynecological Endocrinology, 2013, 29, 79-82.	0.7	36

PAOLO G ARTINI

#	Article	IF	CITATIONS
37	Conventional IVF as a laboratory strategy to rescue fertility potential in severe poor responder patients: the impact of reproductive aging. Gynecological Endocrinology, 2013, 29, 997-1001.	0.7	14
38	Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecological Endocrinology, 2013, 29, 375-379.	0.7	100
39	Infertility and pregnancy loss in euthyroid women with thyroid autoimmunity. Gynecological Endocrinology, 2013, 29, 36-41.	0.7	42
40	Comparison of different anaesthetic methodologies for sedation during <i>in vitro</i> fertilization procedures: effects on patient physiology and oocyte competence. Gynecological Endocrinology, 2012, 28, 796-799.	0.7	26
41	DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecological Endocrinology, 2012, 28, 669-673.	0.7	41
42	Polycystic ovary syndrome: brain-derived neurotrophic factor (BDNF) plasma and follicular fluid levels. Gynecological Endocrinology, 2012, 28, 241-244.	0.7	18
43	Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology, 2012, 28, 969-973.	0.7	71
44	Comparison between GnRH agonist and antagonist protocols for severe endometriosis in assisted reproductive cycles. Journal of Endometriosis, 2012, 4, 42-47.	1.0	3
45	Cenetic screening in Italian infertile couples undergoing intrauterine insemination andin vitrofertilization techniques: a multicentric study. Gynecological Endocrinology, 2011, 27, 453-457.	0.7	8
46	Effects of reproductive aging and postovulatory aging on the maintenance of biological competence after oocyte vitrification: insights from the mouse model. Theriogenology, 2011, 76, 864-873.	0.9	52
47	Difficult-to-treat women for controlled ovarian hyperstimulation: tips and tricks. Expert Review of Endocrinology and Metabolism, 2011, 6, 617-627.	1.2	2
48	Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study. Reproductive BioMedicine Online, 2011, 22, 615-620.	1.1	30
49	Female Infertility Related to Thyroid Autoimmunity: The Ovarian Follicle Hypothesis. American Journal of Reproductive Immunology, 2011, 66, 108-114.	1.2	136
50	Daily Variation of Plasma Brain-derived Neurotrophic Factor in Women with Endometriosis. Journal of Endometriosis, 2011, 3, 40-46.	1.0	1
51	Brain-Derived Neurotrophic Factor in Plasma of Women with Endometriosis. Journal of Endometriosis, 2010, 2, 144-150.	1.0	18
52	Pharmacotherapy of ovarian hyperstimulation syndrome. Expert Opinion on Pharmacotherapy, 2010, 11, 2527-2534.	0.9	5
53	<scp>l</scp> -arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study. Gynecological Endocrinology, 2010, 26, 861-868.	0.7	9
54	Office Vaginoscopic Hysteroscopy in Infertile Women: Effects of Gynecologist Experience, Instrument Size, and Distention Medium on Patient Discomfort. Journal of Minimally Invasive Gynecology, 2010, 17, 344-350.	0.3	40

Paolo G Artini

#	Article	IF	CITATIONS
55	Cryopreservation and oxidative stress in reproductive cells. Gynecological Endocrinology, 2010, 26, 563-567.	0.7	132
56	Chromosomal abnormalities in women with premature ovarian failure. Gynecological Endocrinology, 2010, 26, 717-724.	0.7	7
57	Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Human Fertility, 2009, 12, 40-44.	0.7	50
58	Follicular fluid VEGF levels directly correlate with perifollicular blood flow in normoresponder patients undergoing IVF. Journal of Assisted Reproduction and Genetics, 2008, 25, 183-186.	1.2	49
59	Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomedicine and Pharmacotherapy, 2008, 62, 373-377.	2.5	14
60	Cellular and molecular aspects of ovarian follicle ageing. Human Reproduction Update, 2008, 14, 131-142.	5.2	342
61	Vascular endothelial growth factor level changes during human embryo development in culture medium. Gynecological Endocrinology, 2008, 24, 184-187.	0.7	9
62	Impact of Italian legislation regulating assisted reproduction techniques on ICSI outcomes in severe male factor infertility: a multicentric survey. Human Reproduction, 2007, 22, 2481-2487.	0.4	13
63	Growth factors and folliculogenesis in polycystic ovary patients. Expert Review of Endocrinology and Metabolism, 2007, 2, 215-223.	1.2	22
64	Brain derived neurotrophic factor circulating levels in patients undergoing IVF. Journal of Assisted Reproduction and Genetics, 2007, 24, 477-480.	1.2	22
65	Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecological Endocrinology, 2006, 22, 465-470.	0.7	60
66	Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. Ultrasound in Obstetrics and Gynecology, 2005, 26, 546-551.	0.9	10
67	Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecological Endocrinology, 2005, 21, 340-352.	0.7	25
68	Vascular endothelial growth factor and its soluble receptor in ovarian pathology. Gynecological Endocrinology, 2005, 21, 50-56.	0.7	11
69	Transdermal hormone replacement therapy and Doppler findings in normal and overweight postmenopausal patients. Gynecological Endocrinology, 2004, 19, 274-281.	0.7	10
70	A randomized control comparison study of culture media (HTF versus P1) for human in vitro fertilization. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2004, 116, 196-200.	0.5	10
71	Vascular endothelial growth factor in females of reproductive age. Gynecological Endocrinology, 2003, 17, 477-492.	0.7	12
72	Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 101, 169-174.	0.5	32

PAOLO G ARTINI

#	Article	IF	CITATIONS
73	Membrane integrity evaluation in rabbit spermatozoa. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2002, 102, 53-56.	0.5	37
74	Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertility and Sterility, 2001, 75, 1218-1221.	0.5	54
75	Ultrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations. Ultrasound in Obstetrics and Gynecology, 1998, 11, 332-336.	0.9	45
76	Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome. Ultrasound in Obstetrics and Gynecology, 1998, 12, 180-187.	0.9	20
77	Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertility and Sterility, 1998, 70, 560-564.	0.5	71
78	Colour Doppler changes and thromboxane production after ovarian stimulation with gonadotrophin-releasing hormone agonist. Human Reproduction, 1997, 12, 2477-2482.	0.4	53
79	Clinical utility of adjuvant growth hormone in the treatment of patients with polycystic ovaries undergoing in vitro fertilization. Journal of Assisted Reproduction and Genetics, 1997, 14, 4-7.	1.2	1
80	Intrafollicular insulin-like growth factor-II levels in normally ovulating women and in patients with polycystic ovary syndrome. Fertility and Sterility, 1996, 65, 739-745.	0.5	32
81	Color Doppler hysterosalpingography in the diagnosis of tubal patency. Fertility and Sterility, 1996, 65, 317-322.	0.5	12
82	Hemodynamic, hematological and hemorrheological evaluation of post-term pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1995, 74, 336-340.	1.3	12
83	Activin ?A subunit is expressed in bovine oviduct. Molecular Reproduction and Development, 1995, 40, 286-291.	1.0	30
84	Doppler analysis of uterine blood flow changes in spontaneous and medically induced menopause. Gynecological Endocrinology, 1995, 9, 143-148.	0.7	13
85	Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats. European Journal of Endocrinology, 1995, 133, 375-380.	1.9	77
86	The role of color doppler imaging in the diagnosis of polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 1995, 172, 108-113.	0.7	130
87	Uterine and ovarian blood flow measurement. Does the full bladder modify the flow resistance?. Acta Obstetricia Et Gynecologica Scandinavica, 1994, 73, 716-718.	1.3	33
88	Evidence that granulosa cells inhibit interleukin-1? and interleukin-2 production from follicular lymphomonocytes. Journal of Assisted Reproduction and Genetics, 1993, 10, 517-522.	1.2	11
89	A comparative study of three ovulation induction protocols in polycystic ovarian disease patients in an in vitro fertilization/embryo transfer program. Journal of Assisted Reproduction and Genetics, 1993, 10, 15-20.	1.2	9
90	Doppler Analysis in Pregnancies Complicated by Pregnancy-Induced Hypertension and Fetal Growth Retardation. Hypertension in Pregnancy, 1993, 12, 121-127.	0.5	0

Paolo G Artini

#	Article	IF	CITATIONS
91	Follicular fluid steroid and epidermal growth factor content, and in vitro estrogen release by granulosa-luteal cells from patients with polycystic ovaries in an IVF/ET program. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1991, 42, 195-199.	0.5	27
92	Pregnancy following regression of uterine submucosal leiomyoma with GnRH therapy; a case report. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1991, 39, 223-225.	0.5	4
93	Progestins Modulate the Action of Estrogen on Gonadotropin-Releasing Hormone, Luteinizing Hormone and Prolactin in the Rat. Gynecologic and Obstetric Investigation, 1990, 29, 197-202.	0.7	10
94	Ovarian response to combined growth hormone-gonadotropin treatment in patients resistant to induction of superovulation. Gynecological Endocrinology, 1989, 3, 125-133.	0.7	63